← CLOVER HEALTH INVESTMENTS, CORP. /DE
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($363.7m) | ($6.7m) | ($587.8m) | ($338.8m) | ($213.4m) | ($43.0m) | ($85.5m) | — | |
| Depreciation and amortization expense | $551k | $555k | $1.2m | $1.2m | $2.5m | $1.3m | $1.7m | $1.9m | |
| Change in fair value of warrants and amortization of warrants | $2.9m | $80.3m | ($66.1m) | ($900k) | $86k | $50k | $20k | — | |
| Accretion, net of amortization | ($2.9m) | ($195k) | $200k | ($1.5m) | ($4.0m) | ($2.5m) | ($1.8m) | — | |
| Stock-based compensation | $3.3m | $7.1m | $163.7m | $164.3m | $140.9m | $114.3m | $103.7m | $72.4m | |
| Cash paid for shares withheld related to stock-based compensation | — | — | — | — | ($6.2m) | ($16.5m) | ($36.9m) | — | |
| Impairment of goodwill and other intangible assets | — | — | $0 | $0 | $15.9m | $0 | $0 | — | |
| Healthcare receivables | ($14.5m) | ($12.9m) | ($9.3m) | ($22.6m) | $6.4m | $12.6m | ($43.3m) | — | |
| Accounts payable and accrued expenses | $6.3m | $10.8m | $5.3m | $7.6m | $4.7m | ($2.6m) | $1.6m | $1.5m | |
| Change in accrued interest earned | — | — | — | $0 | $0 | ($571k) | $271k | — | |
| Accrued retrospective premiums | $7.5m | ($21.6m) | ($94k) | $14.5m | ($1.7m) | ($19.2m) | ($22.6m) | — | |
| Unpaid claims | $23.9m | $26.1m | $36.9m | $2.6m | ($3.6m) | $19.3m | ($3.1m) | — | |
| Accrued salaries and benefits | ($2.2m) | $186k | $11.2m | $8.8m | ($2.9m) | ($2.0m) | ($3.1m) | — | |
| Other assets | ($470k) | $1.0m | ($19.8m) | ($1.2m) | $1.8m | $2.9m | ($5.9m) | — | |
| Other liabilities | $168k | $1.4m | $979k | $2.5m | $4.5m | $606k | ($2.7m) | — | |
| Net cash (used in) provided by operating activities from continuing operations | ($159.9m) |
($2.2m)
+98.61%
|
($282.3m)
-12576.74%
|
($304.6m)
-7.89%
|
($35.1m)
+88.46%
|
$82.5m
+334.58%
|
($66.9m)
-181.18%
|
$77.0m
+215.09%
|
|
| Net cash used in operating activities from discontinued operations | ($159.9m) |
($2.2m)
+98.61%
|
($282.3m)
-12576.74%
|
$100.7m
+135.66%
|
($109.5m)
-208.78%
|
($47.6m)
+56.53%
|
$0
+100.00%
|
$77.0m | |
| Net cash (used in) provided by operating activities | ($159.9m) |
($2.2m)
+98.61%
|
($282.3m)
-12576.74%
|
($203.9m)
+27.77%
|
($115.9m)
+43.18%
|
$34.8m
+130.07%
|
($66.9m)
-292.09%
|
$77.0m
+215.09%
|
|
| Purchases of property and equipment | ($23k) | ($693k) | ($723k) | ($4.5m) | ($584k) | ($1.6m) | ($2.0m) | ($2.8m) | |
| Purchases of short-term investments, available-for-sale, and held-to-maturity securities | ($505.5m) | ($174.3m) | ($876.3m) | ($369.4m) | ($175.6m) | ($201.2m) | ($205.1m) | — | |
| Proceeds from sales of short-term investments and available-for-sale securities | $269.2m | $248.7m | $126.9m | $13.3m | $60.4m | $83.7m | $185.2m | — | |
| Proceeds from maturities of short-term investments and available-for-sale securities | $46.4m | $63.8m | $314.7m | $472.1m | $255.7m | $119.7m | $26.1m | — | |
| Net cash provided by investing activities | ($181.9m) | ($828.0m) | ($435.4m) | $95.1m | $140.0m | $565k | $4.1m | ($45.5m) | |
| Issuance of common stock, net of early exercise liability | $601k | $1.7m | $6.1m | $1.4m | $1.1m | $709k | $718k | $3.1m | |
| Issuance of common stock under employee stock purchase plan, net of stock issuance costs | $0 | $25k | $283.8m | $0 | $0 | $193k | $1.1m | $3.1m | |
| Repurchases of common stock | $0 | $0 | ($147k) | ($6.4m) | ($6.2m) | ($1.8m) | ($18.3m) | — | |
| Net cash used in financing activities | $334.0m |
$858.2m
+156.97%
|
$925.4m
+7.83%
|
($5.0m)
-100.54%
|
($33.9m)
-582.41%
|
($17.4m)
+48.73%
|
($53.4m)
-207.49%
|
($21.3m)
+60.05%
|
|
| Net (decrease) increase in cash and cash equivalents | ($7.8m) | $24.8m | $207.6m | ($113.8m) | ($9.7m) | $18.0m | ($116.2m) | — | |
| Cash and cash equivalents, beginning of period | $67.6m | $92.3m | $300.0m | $186.2m | $176.5m | $194.5m | $78.3m | — | |
| Restricted cash | — | $0 | $0 | $82.4m | $53.6m | $0 | $0 | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Net realized gains on investment securities | — | ($1.1m) | $53k | $267k | ($20k) | ($480k) | ($979k) | — | |
| Loss on investment | — | $0 | $0 | ($9.2m) | $4.7m | $467k | $0 | — | |
| Premium deficiency reserve benefit | — | — | $110.6m | ($93.5m) | ($7.2m) | $0 | $0 | — | |
| Prepaid expenses | $600k | ($300k) | ($1.6m) | ($3.4m) | $3.7m | $1.2m | ($5.0m) | — | |
| Cash and cash equivalents | — | $28.0m | $300.0m | $103.8m | $122.9m | $194.5m | $78.3m | $188.6m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.